Characterization of potential salivary biomarkers in Behçet's disease
- PMID: 39480601
- DOI: 10.1007/s11739-024-03801-6
Characterization of potential salivary biomarkers in Behçet's disease
Abstract
Diagnosis of Behçet's disease (BD) has always been a challenging task due to the heterogeneity and complexity of the disease, while available literature on BD biomarkers is largely inconclusive. The aim of this study was to evaluate the expression of a panel of salivary biomarkers in a group of BD patients and test their association with BD. The study population comprised 23 BD patients (12 females and 11 males) and a control group of age and gender-matched healthy individuals. Enzyme-linked immunosorbent assays were used to test the expression of 5 salivary proteins including: interleukin 1β (IL-1β), epidermal growth factor (EGF), endothelin, vascular endothelial growth factor (VEGF) and transferrin (TrF). BD activity was evaluated using the International Society for Behçet's disease (ISBD) current activity form. Salivary endothelin, EGF and VEGF were significantly higher in the BD group compared to controls (16.3 Vs. 7.7 pg/ml, 194.5 Vs. 163.4 pg/ml and 262 Vs. 150.2 pg/ml, p<0.05, respectively) whereas TrF was significantly lower in BD group compared to controls (497 Vs. 2206 pg/ml, p<0.001). The correlation analysis showed a trend of a positive linear association between endothelin expression and both BD activity (r=0.41) and BD activity index score (r=0.4), without reaching statistical significance (p>0.05). In conclusion, salivary TrF, endothelin, VEGF and EGF may represent potential biomarkers for BD. These findings require further validation in larger samples and different activity states of BD.
Keywords: Behçet’s disease; Endothelin; Epidermal growth factor; Saliva; Transferrin; Vascular endothelial growth factor.
© 2024. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study was approved by the institutional review board (IRB) at Jordan University of Science and Technology (approval ID: 461/2016 and 2018/118/62) Consent for publication: All participants received written and verbal information about the nature of the study and written consent was obtained from all of them, prior to examination and saliva collection. Competing interests: None to declare.
References
-
- Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2020) One year in review 2020: Behcet’s syndrome. Clin Exp Rheumatol 38 Suppl 127(5):3–10 - PubMed
-
- Ambrose NL, Haskard DO (2013) Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol 9(2):79–89 - PubMed
-
- Behcet H (1937) Uber rezidivierende, aphtose, durch ein virus verursachte geschrwre am mund, am auge und an den genitalien. Dermatol Wochenschr 105:1152–1157
-
- Zouboulis CC, Keitel W (2002) A historical review of early descriptions of Adamantiades-Behcet’s disease. J Investig Dermatol 119(1):201 - PubMed
-
- Cakir N, Dervis E, Benian O, Pamuk O, Sonmezates N, Rahimoglu R, Tuna S, Cetin T, Sarikaya Y (2004) Prevalence of Behçet’s disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 22:S53–S55 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
